MHQ: Clinical IntelligencePowered by SurvivorNet

Health Panel
Clinical Trials

?

Prefer to talk instead of typing?

Answers offered are informational and do not constitute medical advice. Learn more

Health Profile

Enter health info to personalize results.

What is your gender?

What is your age?

Clinical Trials

Clear List

Sign In

Dr. Natalie Rafaeli

Dr. Natalie Rafaeli

Natalie Rafaeli, MD is a specialist in malignant hematology, specifically with expertise in treating blood cancer. Dr. Rafaeli serves as an Assistant Professor in the McGovern Medical School Department of Internal Medicine. Her research focuses on developing novel treatment strategies. Dr. Rafaeli is board certified in Internal Medicine, Hematology, and Medical Oncology.

Dr. Sameh Gaballa On Treating Relapsed Follicular Lymphoma: More Options, But No Clear Data On Sequencing

Dr. Sameh Gaballa On Treating Relapsed Follicular Lymphoma: More Options, But No Clear Data On Sequencing

By Dr. Natalie Rafaeli

Nivolumab Plus AVD Gains FDA Approval for Frontline Advanced Classical Hodgkin Lymphoma

Nivolumab Plus AVD Gains FDA Approval for Frontline Advanced Classical Hodgkin Lymphoma

By Dr. Natalie Rafaeli

Tec-Dara vs. CAR T-Cell Therapy: Sequencing BCMA-Directed Therapy in Multiple Myeloma

Tec-Dara vs. CAR T-Cell Therapy: Sequencing BCMA-Directed Therapy in Multiple Myeloma

By Dr. Natalie Rafaeli

NYU Langone’s Dr. Catherine Diefenbach On What Updated Frontline Approval Of Acalabrutinib + Venetoclax Means For CLL

NYU Langone’s Dr. Catherine Diefenbach On What Updated Frontline Approval Of Acalabrutinib + Venetoclax Means For CLL

By Dr. Natalie Rafaeli

City of Hope’s Dr. Leslie Popplewell On Regulatory Update of Yescarta for Primary CNS Lymphoma

City of Hope’s Dr. Leslie Popplewell On Regulatory Update of Yescarta for Primary CNS Lymphoma

By Dr. Natalie Rafaeli

NYU’s Dr. Catherine Diefenbach On Navigating the Evolving Chemo-Free Landscape in Relapsed Follicular Lymphoma

NYU’s Dr. Catherine Diefenbach On Navigating the Evolving Chemo-Free Landscape in Relapsed Follicular Lymphoma

By Dr. Natalie Rafaeli

Menin Inhibitors in AML: From Salvage Monotherapy to Frontline Combination Strategies

Menin Inhibitors in AML: From Salvage Monotherapy to Frontline Combination Strategies

By Dr. Natalie Rafaeli

Dr. Sagar Lonial On A New Era For Myeloma: MajesTEC-3 and CARTITUDE-4 — Second-Line Immunotherapy Choices & The Possibility of Therapy Discontinuation

Dr. Sagar Lonial On A New Era For Myeloma: MajesTEC-3 and CARTITUDE-4 — Second-Line Immunotherapy Choices & The Possibility of Therapy Discontinuation

By Dr. Natalie Rafaeli

Differentiation Syndrome in the Era of Targeted Therapies for Acute Myeloid Leukemia

Differentiation Syndrome in the Era of Targeted Therapies for Acute Myeloid Leukemia

By Dr. Natalie Rafaeli

PARADIGM Trial: Rethinking Induction Therapy in Fit Patients With AML

PARADIGM Trial: Rethinking Induction Therapy in Fit Patients With AML

By Dr. Natalie Rafaeli

Exploring Chemo-Free Strategies For Elderly or Frail Patients With Diffuse Large B-Cell Lymphoma

Exploring Chemo-Free Strategies For Elderly or Frail Patients With Diffuse Large B-Cell Lymphoma

By Dr. Natalie Rafaeli

Epcoritamab Plus R² Demonstrates Superior Outcomes in Second-Line Follicular Lymphoma

Epcoritamab Plus R² Demonstrates Superior Outcomes in Second-Line Follicular Lymphoma

By Dr. Natalie Rafaeli

ASC4FIRST: Follow-Up Study Shows Improved Efficacy & Safety With Asciminib In First-Line CML

ASC4FIRST: Follow-Up Study Shows Improved Efficacy & Safety With Asciminib In First-Line CML

By Dr. Natalie Rafaeli

Fixed-Duration Vs. Continuous Targeted Therapy in CLL: The CLL17 Trial Provides Much-Needed Answers

Fixed-Duration Vs. Continuous Targeted Therapy in CLL: The CLL17 Trial Provides Much-Needed Answers

By Dr. Natalie Rafaeli

$Experimental BCMA CAR T-Cell Therapy Anito-cel Shows Deepening Responses in Relapsed/Refractory Multiple Myeloma$

Experimental BCMA CAR T-Cell Therapy Anito-cel Shows Deepening Responses in Relapsed/Refractory Multiple Myeloma

By Dr. Natalie Rafaeli

$“A Home Run” For Myeloma: What’s Next After The MajesTEC-3 Practice-Changing Results For Relapsed/Refractory Multiple Myeloma$

“A Home Run” For Myeloma: What’s Next After The MajesTEC-3 Practice-Changing Results For Relapsed/Refractory Multiple Myeloma

By Dr. Natalie Rafaeli